Contents
Contents
The AngioDynamics LC Bead settlement formed part of a $12.5 million resolution of allegations that misleading medical device promotion and billing advice caused false claims to Medicare, Medicaid and other federal healthcare programs. The government described a sales pitch that reached into the provider’s bill: promote a chemotherapy use, then supply inaccurate codes when insurers would not cover it. A separate vein-treatment kit raised a different allegation, that sales personnel promised Medicare coverage despite restrictions. For someone inside medical device sales or reimbursement support, the connection between those conversations and the eventual claim is the heart of this case.
The Department of Justice announced the resolution on July 18, 2018. AngioDynamics, based in Latham, New York, distributed LC Bead for its manufacturer, Biocompatibles. It also sold the Perforator Vein Ablation Kit.
AngioDynamics agreed to pay $11.5 million to resolve the LC Bead allegations. The government alleged that, from May 2006 through December 2011, the company served as Biocompatibles’ U.S. distributor and marketed LC Bead for use with chemotherapy drugs as a drug-delivery medical device.
The Food and Drug Administration had twice declined to approve that use. According to the government, AngioDynamics personnel nevertheless routinely described it as “better”, “superior”, “safer” and “less toxic” than alternative treatments, without sufficient clinical evidence to support those claims.
Those words sold a reason to choose the treatment. The billing instructions allegedly supplied a way to get it paid for. The government said AngioDynamics knew many insurers declined coverage for certain LC Bead procedures and instructed health care providers to use inaccurate billing codes when submitting claims for those uses.
Taxpayers were asked to pay bills that, according to the government, misrepresented the procedures performed.
The whistleblower’s complaint alleged that providers used traditional embolization codes to conceal a drug-eluting treatment:
By encouraging providers to hide the true nature of the DEBTACE procedure using the CPT code for traditional TAE embolization procedures, the Device Defendants have knowingly caused the submission of false claims for non-reimbursable procedures.
Whistleblower’s allegation, United States ex rel. Bliss v. Biocompatibles, Inc., complaint, paragraph 155
Biocompatibles had separately agreed to a $25 million civil settlement in November 2016. AngioDynamics’ later settlement concerned the distributor’s own alleged promotion and billing instructions.
Yes. The LC Bead settlement resolved a False Claims Act case brought by a former marketing employee who had worked at both AngioDynamics and Biocompatibles. The government alleged that AngioDynamics caused health care providers to submit false claims.
The person making the sales representation can sit several steps away from the request for government money.
A 2020 paper in the Journal of Forensic and Investigative Accounting, A Forensic Accountant’s Guide to the Most Potent Federal Laws Used Against Healthcare Fraud, explains why the payment request is central. Its analysis connects false claims to what the defendant knew and whether the conduct induced wrongful payment.
The alleged inaccurate code was the point where a commercial instruction could become part of the provider’s claim.
Medicare usually includes the cost of a medical device used in a procedure within the payment for the procedure or facility service.
The Food and Drug Administration had declined the drug-delivery use, insurers declined coverage for certain procedures, and the government alleged that AngioDynamics responded with inaccurate coding instructions. The alleged false claim was the provider’s procedure bill.
For a reimbursement specialist, the useful comparison is between the procedure the company promoted and the procedure its billing advice described. We examine that connection with insiders because the sales conversation and the bill can sit in different parts of the business.
The Perforator Vein Ablation Kit allegations concerned a product that AngioDynamics recalled and renamed, then allegedly continued to promote for the same unapproved use. The government said personnel also falsely told providers that Medicare would cover that use.
AngioDynamics acquired the kit in 2008 as part of a product suite using a laser to close or collapse malfunctioning veins. The Food and Drug Administration had cleared it only for treatment of superficial veins. In 2011, the company requested that the clearance include perforator veins.
The Food and Drug Administration told AngioDynamics that treating perforator veins was a new indication for which safety and efficacy were unknown. The company voluntarily recalled the kit and reissued it as the 400 micron kit, removing the reference to perforator treatment from the product’s name.
The name changed. According to the government’s allegations, the promotion continued. Certain AngioDynamics personnel kept marketing the medical device for perforator veins and represented that Medicare would pay for the use despite coverage restrictions to the contrary.
AngioDynamics agreed to pay a separate $1 million to resolve the vein-kit allegations.
Vascular Solutions agreed to a $520,000 settlement announced in July 2014 to resolve allegations that it promoted Vari-Lase for perforator-vein ablation without Food and Drug Administration authorization, following a whistleblower case brought by a former sales representative. The whistleblower’s complaint also alleged that representatives were instructed to recommend treating individual veins on separate days to maximize reimbursement.
For the AngioDynamics allegations, the useful evidence connects the promoted use, the company’s knowledge of coverage, the advice given to providers and the resulting claims. That is the connection our whistleblower experts examine with someone who knows the product or the reimbursement work. The journal paper also identifies inside information as a reason whistleblower cases can expose complex financial fraud.
For LC Bead, we look at whether promotional materials and billing instructions concern the same use, and how the information reached the people submitting the claims. For the vein kit, someone familiar with the product before and after the rebranding may be able to explain how the written description compared with what providers were told.
Marketing, sales and reimbursement employees can each know a different part of that story. We bring those perspectives together to assess the connection between the company’s conduct and government money.
A whistleblower case under the False Claims Act can pay 15% to 30% of what the government recovers.
The former marketing employee’s qui tam case concerned LC Bead, and the Justice Department announced that the whistleblower would receive approximately $2.3 million from that settlement component. The same whistleblower had an approximately $5.1 million award from the earlier Biocompatibles civil settlement.
The alleged false claims were provider bills, but the whistleblower came from the commercial side of the product. That is where knowledge of the sales message can help explain why those bills were submitted.
If you saw a medical device sales pitch turn into a false coverage assurance or an inaccurate billing instruction, talk with our whistleblower experts. We build the case with you around what the company promoted, what providers were told and what the government paid, bringing in medical device fraud whistleblower lawyers who understand promotion and reimbursement cases. We stay with you from the first call, working to build your strongest medical device whistleblower case.